Home / Drug discovery / ADME / In vitro toxicology
In vitro toxicology services
Our in vitro toxicology studies pinpoint safety risks early, so you have clear evidence to guide smarter design and safer candidate selection.
Integrated with our ADME platform, these assays connect discovery data with preclinical insight to reduce surprises and keep your program on track.
In vitro ADME services available include:
- Cytotoxicity and genotoxicity screening (e.g., Ames test, micronucleus assay)
- Hepatotoxicity and DILI screening services – including drug-induced liver injury assessment using DILIscope and other mechanistic in vitro models
- Cardiotoxicity screening, hERG inhibition assays
- Mechanistic toxicity assays
Related services
ADME services delivered by Admescope
All ADME-Tox services, including in vitro ADME, in vivo PK screening, in vitro toxicology, and in vivo DMPK are performed by Admescope (a Symeres company), a leading ADME CRO.
In vitro toxicology for smarter, faster paths forward
Biotech and pharma trust us
Extensive experience in early-stage in vitro toxicology
Streamlined startup and turnaround
Proposals and study initiation available through Admeshop for fast startup.
Flexible formats
Fully customizable and underpinned by our expertise, for whatever stage your project is at.
Specialist DILI services
Advanced in vitro models, including DILIscope, to evaluate liver injury risk during early discovery and preclinical development.
ADME-Tox services
In vitro toxicology services link directly with our ADME and in vivo PK studies, so you get connected data from safety, exposure and metabolism in one place.
This integration keeps results comparable, reduces rework and supports confident progression from discovery to preclinical development.
What do our partners say?
“I would like to extend my thanks for the excellent work Symeres has done in synthesizing the API for Part 1 of our project. Your communication throughout the process was outstanding, and the sense of urgency with which you operated allowed us to complete this phase promptly and efficiently.”
Leader
Large biotech
“The progression was really phenomenal. I am truly impressed. There is a world of difference between you and other CROs.”
Start-up Founder
Biotech
“They’ve always met or exceeded my expectations - that’s why I continue to come back, company after company, year after year.”
Allen Horhota, Vice-President Platform & Delivery
Seamless Therapeutics
“If the compound can be made, Symeres will undoubtedly find out a good way to make it.”
Dooyoung Jung, CEO
Pinotbio
“Through our dedicated FTE resource at Symeres we have achieved remarkable results, not only by developing a new “aspirational” synthetic route but also by significantly improving the current one to deliver a sustainable route for commercial production and giving us two options for late development.”
Associate Director
Large pharma, Europe
“We are developing the most complex molecule that is built at this time in the world…We work with a lot of CROs, also chemistry CROs, and so far Symeres has done the best job with respect to transparency and also to troubleshoot the problems and find a solution. Over the years we have been really impressed with the work that Symeres has done.”
Founder
Biotech
“The team is making short work of these targets, so we will have to start thinking of some additional targets!”
Director
Biotech
“A sign that things are going well - we keep coming to you. We’ve given Symeres five or six different projects already. That’s almost unheard of for us.“
Senior Director, Manufacturing
Top 10 global pharma
“We’ve been with them…over 10 years. The cost, the flexibility - the value is just so strong. That’s why we’ve stuck with them.”
Senior Director, CMC
Biotech
Resources we think you'll love
Blog
CDMO red flags you can’t ignore: Regulatory shortfalls and misalignment
Whitepaper
5 CDMO red flags you can’t ignore: A guide for biotechs and pharma
Blog
CDMO red flags you can’t ignore: Underestimating technology transfer complexity
Blog
O.N.E Symeres: A practical approach to real-world drug development
Blog
CDMO red flags you can’t ignore: Undefined or shifting project scope
Whitepaper
Accelerating chemical innovation: Unveiling Symeres’ parallel chemistry
Webinar | On-demand
From racemic to pure the art and science of enantiomer separation
Whitepaper
IND & IMPD enabling developability roadmap
Whitepaper
Innovations in unnatural amino acids: Advancing functional diversity and applications
Whitepaper
Leveraging copper-catalyzed ullmann-type cross-coupling reactions in PR&D
Whitepaper
Managing nitrosamines in the pharmaceutical industry: A comprehensive approach
Whitepaper
Optimizing solid-state properties and enhancing API bioavailability through physicochemical prediction
Whitepaper
Stable isotope-labeled compounds
Whitepaper
Unlocking the potential of high-throughput screening: Symegold library design and expansion insights
Interviews
Insights into drug discovery and development 2025
Interviews
Interview with the computer-aided drug design (CADD) department
Interviews
Meet the Organix Director, Mario Gonzalez
Interviews
Interview with the new Managing Director of Symeres Groningen
Interviews
An interview with Yadan Chen and Paul O’Shea
Interviews
An interview with Anu Mahadevan and Paul Blundell
Blog
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
Webinar | On-demand
In vivo pharmacokinetic experiments in preclinical drug development
Webinar | On-demand
Accelerating medicinal chemistry by rapid analoging
Webinar | On-demand
Solid-state chemistry part II: Optimal form selection by controlled crystallization
Webinar | On-demand
Route scouting for kilogram-scale manufacturing of APIs
Webinar | On-demand
Solid-state chemistry part I: Introduction
Speak with our in vitro toxicology experts
Let us support the discovery and development of your next breakthrough.